Advertisement

International Journal of Clinical Pharmacy

, Volume 37, Issue 3, pp 475–484 | Cite as

Potential drug–drug interactions in hospitalized patients undergoing systemic chemotherapy: a prospective cohort study

  • Paula StollEmail author
  • Luciane Kopittke
Research Article

Abstract

Background Adverse drug–drug interactions (DDI) are a major cause of morbidity and mortality in susceptible populations. Cancer patients are a population at high risk for DDI especially because they commonly receive several drugs concomitantly. The knowledge about the most common interactions between drugs used in oncology inpatients is essential to reduce drug-related problems and increase the safety and efficacy of the therapy. Objective To assess the frequency of potential DDI throughout the hospital stay of cancer patients undergoing systemic chemotherapy, describe their epidemiology, and identify risk factors for major DDI. Setting An oncology–hematology inpatient unit of a public hospital in southern Brazil. Method Drug prescriptions were prospectively reviewed throughout the hospital stay of patients admitted for systemic chemotherapy. Descriptive statistics and Poisson regression were used for data analysis. Main outcome measure Potential DDI and their characteristics. Results The cohort consisted of 113 patients, who used a mean of 8.9 ± 2.7 drugs/day. All patients had at least one potential DDI (median, 7.0/patient; 25th–75th percentile, 3.5–12.0), and 46 % of the patients had at least one DDI classified as major, i.e. that it may result in death, hospitalization, permanent injury, or therapeutic failure. Only 13.7 % of all interactions involved antineoplastic agents, identified in 62.8 % of patients. Most interactions were of moderate severity, 6.4 % were major, and 8.5 % had a recommendation for therapy modification. Multivariate analysis revealed mean number of drugs prescribed [relative risk (RR) for each additional drug: 1.12; 95 % confidence interval (CI) 1.07–1.17; P < 0.01] and age ≥60 years (RR 1.48; 95 % CI 1.03–2.14; P < 0.01) as independent risk factors for major DDI. Conclusion Potential DDI were highly frequent in this cohort. Older age and number of drugs prescribed were more likely to lead to major interactions. Prospective surveillance is required to detect adverse DDI, aiming primarily at reducing the risk of toxicity or treatment failure.

Keywords

Cancer patients Chemotherapy Drug–drug interactions Drug-related problems Risk factors 

Notes

Funding

The translation and submission of this article was supported by Glenmark Farmacêutica Ltda.

Conflicts of interest

The authors declare that there are no conflicts of interest.

References

  1. 1.
    Hartshorn EA. Drug interaction: 1. General considerations. Ann Pharmacother. 2006;40:116–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer. 2006;6:546–58.CrossRefPubMedGoogle Scholar
  3. 3.
    Blower P, de Wit R, Goodin S, Aapro M. Drug–drug interactions in oncology: why are they important and can they be minimized? Crit Rev Oncol Hematol. 2005;55:117–42.CrossRefPubMedGoogle Scholar
  4. 4.
    Riechelmann RP, Moreira F, Smaletz O, Saad ED. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol. 2005;56:286–90.CrossRefPubMedGoogle Scholar
  5. 5.
    Haddad A, Davis M, Lagman R. The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions. Support Care Cancer. 2007;15:251–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Haidar C, Jeha S. Drug interactions in childhood cancer. Lancet Oncol. 2011;12:92–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Riechelmann RP, Saad ED. A systematic review on drug interactions in oncology. Cancer Invest. 2006;24:704–12.CrossRefPubMedGoogle Scholar
  8. 8.
    Riechelmann RP, Zimmermann C, Chin SN, et al. Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manag. 2008;35:535–43.CrossRefGoogle Scholar
  9. 9.
    Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007;99:592–600.CrossRefPubMedGoogle Scholar
  10. 10.
    Jansman FG, Reyners AK, van Roon EN, et al. Consensus-based evaluation of clinical significance and management of anticancer drug interactions. Clin Ther. 2011;33:305–14.CrossRefPubMedGoogle Scholar
  11. 11.
    Riechelmann RP, Del Giglio A. Drug interactions in oncology: how common are they? Ann Oncol. 2009;20:1907–12.CrossRefPubMedGoogle Scholar
  12. 12.
    Voll ML, Yap KD, Terpstra WE, Crul M. Potential drug–drug interactions between anti-cancer agents and community pharmacy dispensed drugs. Pharm World Sci. 2010;32:575–80.CrossRefPubMedGoogle Scholar
  13. 13.
    van Leeuwen RW, Swart EL, Boven E, Boom FA, Schuitenmaker MG, Hugtenburg JG. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol. 2011;22:2334–41.CrossRefPubMedGoogle Scholar
  14. 14.
    Hadjibabaie M, Badri S, Ataei S, Moslehi AM, Karimzadeh I, Ghavamzadeh A. Potential drug–drug interactions at a referral hematology–oncology ward in Iran: a cross-sectional study. Cancer Chemother Pharmacol. 2013;71:1619–27.CrossRefPubMedGoogle Scholar
  15. 15.
    Lexi-Interact. http://webstore.lexi.com/Lexi-Interact. Accessed 1 Nov 2009.
  16. 16.
    Barrons R. Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm. 2004;61:380–5.PubMedGoogle Scholar
  17. 17.
    Reis AM, Cassiani SH. Evaluation of three brands of drug interaction software for use in intensive care units. Pharm World Sci. 2010;32:822–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Vonbach P, Dubied A, Krähenbuhl S, Beer JH. Evaluation of frequently used drug interaction screening programs. Pharm World Sci. 2008;30:367–74.CrossRefPubMedGoogle Scholar
  19. 19.
    Puts MT, Monette J, Girre V, et al. Potential medication problems in older newly diagnosed cancer patients in Canada during cancer treatment: a prospective pilot cohort study. Drugs Aging. 2010;27:559–72.CrossRefPubMedGoogle Scholar
  20. 20.
    McLeod HL. Clinically relevant drug–drug interactions in oncology. Br J Clin Pharmacol. 1998;45:539–44.CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Egger SS, Drewe J, Schlienger RG. Potential drug–drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol. 2003;58:773–8.PubMedGoogle Scholar
  22. 22.
    Sokol KC, Knudsen JF, Li MM. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther. 2007;32:169–75.CrossRefPubMedGoogle Scholar
  23. 23.
    Miranda V, Fede A, Nobuo M, et al. Adverse drug reactions and drug interactions as causes of hospital admission in oncology. J Pain Symptom Manag. 2011;42:342–53.CrossRefGoogle Scholar
  24. 24.
    Riechelmann RP. Drug combinations with the potential to interact among cancer patients. Support Care Cancer. 2007;15:1113–4.CrossRefPubMedGoogle Scholar
  25. 25.
    Peral Aguirregoitia J, Lertxundi Etxebarria U, Martínez Bengoechea MJ, Mora Atorrasagasti O, Franco Lamela E, Gabilondo Zelaia I. Prospective assessment of drug interactions in hospitalized patients using a computer programme. Farm Hosp. 2007;31:93–100.CrossRefPubMedGoogle Scholar
  26. 26.
    Norton PG, Baker GR. Patient safety in cancer care: a time for action. J Natl Cancer Inst. 2007;99:579–80.CrossRefPubMedGoogle Scholar
  27. 27.
    Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med. 2006;166:955–64.CrossRefPubMedGoogle Scholar
  28. 28.
    Bremberg ER, Hising C, Nylén U, Ehrsson H, Eksborg S. An evaluation of pharmacist contribution to an oncology ward in a Swedish hospital. J Oncol Pharm Pract. 2006;12:75–81.CrossRefPubMedGoogle Scholar
  29. 29.
    Cavero Rodrigo E, Climente Martí M, Navarro Fontestad MC, Jiménez Torres NV. Quality assessment of two pharmaceutical care models for oncohaematological patients. Farm Hosp. 2007;31:231–7.CrossRefPubMedGoogle Scholar

Copyright information

© Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2015

Authors and Affiliations

  1. 1.Grupo Hospitalar ConceiçãoPorto AlegreBrazil

Personalised recommendations